Loading...
The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
There is a plethora of published cancer biomarkers but the reality is that very few, if any, new circulating cancer biomarkers have entered the clinic in the last 30 years. I here try to explain this apparent oxymoron by classifying circulating cancer biomarkers into three categories: fraudulent rep...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3425158/ https://ncbi.nlm.nih.gov/pubmed/22876833 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1741-7015-10-87 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|